Cargando…
Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model
BACKGROUND AND AIM: Toxocara vitulorum is a bovine intestinal nematode. Immune pictures following infection are conflicting and stopping anthelmintic albendazole treatment recording reversed liver abnormalities. The purpose of this work was to evaluate the therapeutic potential of bone marrow mesenc...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Veterinary World
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994112/ https://www.ncbi.nlm.nih.gov/pubmed/33776300 http://dx.doi.org/10.14202/vetworld.2021.347-363 |
_version_ | 1783669696166363136 |
---|---|
author | Abo-Aziza, Faten A. M. Zaki, Abdel Kader A. Alajaji, Ahmed I. Al barrak, Saleh M. |
author_facet | Abo-Aziza, Faten A. M. Zaki, Abdel Kader A. Alajaji, Ahmed I. Al barrak, Saleh M. |
author_sort | Abo-Aziza, Faten A. M. |
collection | PubMed |
description | BACKGROUND AND AIM: Toxocara vitulorum is a bovine intestinal nematode. Immune pictures following infection are conflicting and stopping anthelmintic albendazole treatment recording reversed liver abnormalities. The purpose of this work was to evaluate the therapeutic potential of bone marrow mesenchymal stem cells (BMMSCs) therapy, subsequent to albendazole administration in rats infected with T. vitulorum. MATERIALS AND METHODS: The ultrasonographic and histopathological examinations as well as serum liver enzymes activity and the kinetics of recovery were investigated. The correlation of cell-mediated and humoral immune pictures was assessed by assaying immunoglobulins, splenocytes viability, phagocytic index, and Th1/Th2 cytokines. RESULTS: The cultured BMMSCs counting were 4.21×10(4) cells/cm(2) with 96.03% viability. Flow-cytometric analysis indicated positive CD90 (82%), CD105 (79%) and negative CD34 (0.37%), CD45 (0.42%), attesting to the suitability of the isolated BMMSCs for use in therapy. Transplantation of BMMSCs after albendazole administration significantly reduced the release of liver enzymes (p<0.05) indicating liver cellularity improvement. The ultrasonographic, macroscopic, and histopathological findings confirmed the biochemical results. Significant elevation in the levels of tumor necrosis factor (TNF)-α and interferon (INF)-γ with a decline in interleukin (IL)-4 was observed in the untreated model (p<0.05). However, albendazole treatment followed by BMMSCs therapy significantly lowered the release of TNF-α and INF-γ, associated with significant production of IL-4 and IL-10 (p<0.05). CONCLUSION: The final results indicated that the liver functions, histopathological findings, and immune parameters were aggravated after experimental T. vitulorum infection. Albendazole treatment followed by BMMSCs therapy was found to assist in regeneration of injured hepatic tissue. Besides, it appeared to modulate host defensive immune responses against T. vitulorum antigens. This work could define more clearly the events that manipulate the host immune, histopathological, and biochemical responses to minimize obstacles in using stem cell therapy in animal toxocariosis. |
format | Online Article Text |
id | pubmed-7994112 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Veterinary World |
record_format | MEDLINE/PubMed |
spelling | pubmed-79941122021-03-27 Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model Abo-Aziza, Faten A. M. Zaki, Abdel Kader A. Alajaji, Ahmed I. Al barrak, Saleh M. Vet World Research Article BACKGROUND AND AIM: Toxocara vitulorum is a bovine intestinal nematode. Immune pictures following infection are conflicting and stopping anthelmintic albendazole treatment recording reversed liver abnormalities. The purpose of this work was to evaluate the therapeutic potential of bone marrow mesenchymal stem cells (BMMSCs) therapy, subsequent to albendazole administration in rats infected with T. vitulorum. MATERIALS AND METHODS: The ultrasonographic and histopathological examinations as well as serum liver enzymes activity and the kinetics of recovery were investigated. The correlation of cell-mediated and humoral immune pictures was assessed by assaying immunoglobulins, splenocytes viability, phagocytic index, and Th1/Th2 cytokines. RESULTS: The cultured BMMSCs counting were 4.21×10(4) cells/cm(2) with 96.03% viability. Flow-cytometric analysis indicated positive CD90 (82%), CD105 (79%) and negative CD34 (0.37%), CD45 (0.42%), attesting to the suitability of the isolated BMMSCs for use in therapy. Transplantation of BMMSCs after albendazole administration significantly reduced the release of liver enzymes (p<0.05) indicating liver cellularity improvement. The ultrasonographic, macroscopic, and histopathological findings confirmed the biochemical results. Significant elevation in the levels of tumor necrosis factor (TNF)-α and interferon (INF)-γ with a decline in interleukin (IL)-4 was observed in the untreated model (p<0.05). However, albendazole treatment followed by BMMSCs therapy significantly lowered the release of TNF-α and INF-γ, associated with significant production of IL-4 and IL-10 (p<0.05). CONCLUSION: The final results indicated that the liver functions, histopathological findings, and immune parameters were aggravated after experimental T. vitulorum infection. Albendazole treatment followed by BMMSCs therapy was found to assist in regeneration of injured hepatic tissue. Besides, it appeared to modulate host defensive immune responses against T. vitulorum antigens. This work could define more clearly the events that manipulate the host immune, histopathological, and biochemical responses to minimize obstacles in using stem cell therapy in animal toxocariosis. Veterinary World 2021-02 2021-02-08 /pmc/articles/PMC7994112/ /pubmed/33776300 http://dx.doi.org/10.14202/vetworld.2021.347-363 Text en Copyright: © Abo-Aziza, et al. http://creativecommons.org/licenses/by/4.0 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Abo-Aziza, Faten A. M. Zaki, Abdel Kader A. Alajaji, Ahmed I. Al barrak, Saleh M. Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model |
title | Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model |
title_full | Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model |
title_fullStr | Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model |
title_full_unstemmed | Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model |
title_short | Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model |
title_sort | bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing toxocara vitulorum-rat model |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994112/ https://www.ncbi.nlm.nih.gov/pubmed/33776300 http://dx.doi.org/10.14202/vetworld.2021.347-363 |
work_keys_str_mv | AT aboazizafatenam bonemarrowmesenchymalstemcellcoadjuvanttherapywithalbendazoleformanagingtoxocaravitulorumratmodel AT zakiabdelkadera bonemarrowmesenchymalstemcellcoadjuvanttherapywithalbendazoleformanagingtoxocaravitulorumratmodel AT alajajiahmedi bonemarrowmesenchymalstemcellcoadjuvanttherapywithalbendazoleformanagingtoxocaravitulorumratmodel AT albarraksalehm bonemarrowmesenchymalstemcellcoadjuvanttherapywithalbendazoleformanagingtoxocaravitulorumratmodel |